Android app Apple app link

Novartis' Phase III spinal muscular atrophy therapy trial meets primary endpoint

By Yahoo! Finance   |   4 days ago
Novartis' Phase III spinal muscular atrophy therapy trial meets primary endpoint

Novartis announced positive results from the Phase III STEER trial of OAV101 IT gene therapy for SMA Type 2 patients. The study showed improved motor function in treated subjects compared to controls, with a favorable safety profile. Novartis plans to seek regulatory approval in 2025.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.